Medrx Co

Medrx Co Capital Intensity

The Capital Intensity Ratio of Medrx Co (4586.T) as of Nov 19, 2026 is 1,684.47 %. In the previous year, Capital Intensity Ratio was 882.07 % — a change of 90.97% (higher).

Capital Intensity

1,684.47 %

YoY

90.97%

Last updated:

Capital Intensity Ratio of Medrx Co is 2025 1,684.47 % . Capital Intensity Ratio of Medrx Co was 2024 882.07 % . It decreases by 90.97% higher compared to the previous year.

The Medrx Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
27,527.39 JPY
Jan 1, 2019
1,205.50 JPY
Jan 1, 2020
1,996.11 JPY
Jan 1, 2021
25,252.56 JPY
Jan 1, 2022
2,350.74 JPY
Jan 1, 2023
6,947.92 JPY
Jan 1, 2024
882.07 JPY
Jan 1, 2025
1,684.47 JPY
The Medrx Co Capital Intensity history
YEARCapital IntensityYoY
1,684.47 %+90.97%
882.07 %-87.30%
6,947.92 %+195.56%
2,350.74 %-90.69%
25,252.56 %+1,165.09%
1,996.11 %+65.58%
1,205.50 %-95.62%
27,527.39 %+2,457.88%
1,076.18 %-92.19%
13,782.23 %+74.08%
7,917.30 %-43.53%
14,019.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Capital Intensity Ratio of Medrx Co is 1,684.47 % in 2025.

Capital Intensity Ratio of Medrx Co changed from 882.07 % to 1,684.47 %, representing a 90.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co